Cost & Financial
    Employer Benefits

    How to Get Your Employer to Cover GLP-1 Medications

    A strategic guide to building the case for employer-sponsored weight loss medication coverage.

    Last updated: April 3, 2026·14 min read

    As GLP-1 medications prove their effectiveness for weight loss and related health conditions, a growing number of employers are adding coverage to their benefits packages. If your employer does not currently cover semaglutide or tirzepatide, you can advocate for change. The key is presenting a compelling business case that speaks to both employee wellbeing and the company's bottom line.

    The Business Case for Employer GLP-1 Coverage

    Employer Cost of Obesity (Per Employee/Year)

    • Excess medical claims: $2,505/year average for obese employees vs. normal-weight
    • Absenteeism: 5-10 additional sick days per year ($1,200-2,600 in lost productivity)
    • Presenteeism: 12-15% reduced on-the-job productivity ($3,000-5,000/year)
    • Workers' comp: Obese workers file twice as many claims at 7x the cost
    • Disability: Obesity increases short-term and long-term disability claims by 76%
    • Total employer cost of obesity: $6,700-10,000+/employee/year

    ROI Data to Present to HR

    When approaching your HR team, lead with numbers:

    • 3-year ROI: Studies show that employer-sponsored GLP-1 programs return $2-4 for every $1 invested through reduced medical claims and improved productivity
    • Medical claims reduction: Employees who achieve 10%+ weight loss see 20-30% lower medical claims over 3 years
    • Diabetes prevention: Each diabetes case prevented saves the employer approximately $9,600/year in excess costs
    • Cardiovascular risk: The SELECT trial showed 20% reduction in cardiovascular events with semaglutide, translating to fewer expensive hospitalizations
    • Retention: Employees value health benefits highly; adding innovative benefits improves retention and recruitment

    Step-by-Step: How to Approach Your Employer

    1. Identify the right contact. For large companies: Director of Benefits, VP of HR, or Chief People Officer. For smaller companies: HR Manager or business owner. Benefits consultants and brokers are often the true decision-makers.
    2. Time it right. Approach during the benefits planning cycle (typically 3-6 months before plan renewal). Open enrollment discussions are when benefit changes are most seriously considered.
    3. Frame it as a business proposal, not a personal request. Lead with the ROI data, not your personal need. Present it as a benefit that could help many employees.
    4. Gather allies. If multiple employees express interest, it carries more weight. An employee petition or wellness committee recommendation is powerful.
    5. Propose a pilot program. Suggest a limited pilot (50-100 employees, 6-12 months) with measurable outcomes. This reduces risk for the employer while generating internal data.
    6. Offer alternatives to full pharmacy coverage. HRA contributions, telehealth partnerships, or wellness stipends may be easier to implement than full insurance coverage.

    Coverage Models Employers Can Implement

    1. Full Pharmacy Benefit Coverage

    Adding GLP-1 medications to the pharmacy formulary. Most expensive option but most comprehensive. Typically includes prior authorization requirements. Works best for self-insured employers who control their formulary.

    2. Telehealth Partnership

    Partnering with a telehealth GLP-1 provider (like Trimi Health) as a standalone benefit. Lower cost than full pharmacy coverage. Includes medical oversight, medication, and support. Can be offered as an employee perk without changing the insurance plan.

    3. Health Reimbursement Arrangement (HRA)

    The employer contributes a set amount to an HRA that employees can use for GLP-1 treatment. Gives employees choice of provider while limiting employer cost. Can be targeted to employees with qualifying health conditions.

    4. Wellness Stipend

    A monthly wellness allowance that employees can apply toward GLP-1 treatment. Simplest to implement. No pharmacy benefit changes needed. Employees handle their own provider selection.

    Email Template for HR

    Sample Email to HR/Benefits Team

    Subject: Proposal: GLP-1 Weight Loss Medication Benefit

    Dear [HR/Benefits Contact],

    I am writing to propose that [Company Name] consider adding GLP-1 weight loss medication coverage to our benefits package. With over 40% of American adults affected by obesity, this benefit would serve a significant portion of our workforce.

    The business case is compelling: obesity costs employers an estimated $6,700-10,000 per affected employee annually in excess medical claims, absenteeism, and reduced productivity. Research shows that GLP-1 treatment returns $2-4 for every $1 invested over 3 years through reduced healthcare utilization.

    I would welcome the opportunity to discuss coverage options, including lower-cost alternatives to full pharmacy coverage such as telehealth partnerships or wellness stipends. A pilot program could demonstrate ROI with minimal risk.

    Would you be open to a brief conversation about this during the upcoming benefits planning cycle?

    If Your Employer Says No

    • Ask about timeline. Many employers are evaluating GLP-1 coverage for future plan years. Knowing the timeline helps you plan.
    • Request HSA contribution increases. Higher employer HSA contributions can offset GLP-1 costs.
    • Use existing benefits creatively. HSA/FSA accounts, wellness reimbursements, and EAP benefits may partially cover GLP-1 costs.
    • Explore affordable alternatives. Compounded GLP-1 medications at $200-500/month are accessible without employer coverage.
    • Try again next year. Benefits decisions are made annually. Present updated data and employee interest each cycle.

    Key Takeaways

    • Obesity costs employers $6,700-10,000+ per affected employee annually
    • GLP-1 treatment ROI for employers is $2-4 returned for every $1 invested
    • Present the business case, not just personal need, when approaching HR
    • Propose a pilot program to minimize employer risk
    • Multiple coverage models exist beyond full pharmacy benefits
    • If coverage is declined, use HSA/FSA and affordable compounded options

    Disclaimer: This article is for informational purposes only. Employer benefits decisions involve legal, financial, and regulatory considerations beyond the scope of this article. Consult with benefits professionals for specific guidance.

    Employer Partnership Programs

    Trimi Health offers employer partnership programs for companies looking to provide GLP-1 benefits to their workforce.

    Learn More

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the current clinical evidence support for GLP-1-based weight management?

    GLP-1 receptor agonists (semaglutide, tirzepatide) have Phase 3 RCT evidence for chronic weight management in adults with BMI ≥30 or BMI ≥27 with a weight-related comorbidity. Trimi offers compounded preparations of the same active ingredients at $99/month (semaglutide) and $125/month (tirzepatide) on the annual plan, prepared per individual prescription by 503A community sterile compounding pharmacies and reviewed by a US-licensed clinician through Beluga Health's 50-state physician network. Compounded preparations are not themselves FDA-approved as drugs; the active ingredients are FDA-approved in the corresponding brand finished products. Eligibility is determined by a licensed clinician.

    Phase 3 RCT evidence base: STEP 1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), SELECT (NEJM 2023), FLOW (NEJM 2024)
    Trimi pricing: $99/month semaglutide / $125/month tirzepatide on annual plan
    Clinical review: Dr. Asad Niazi, MD MPH via Beluga Health 50-state network

    Key Takeaways

    • Compounded semaglutide and compounded tirzepatide are prepared per individual prescription by 503A community sterile compounding pharmacies (VialsRx — Texas State Board pharmacy license #35264 — and GreenwichRx). The active ingredients (semaglutide, tirzepatide) are FDA-approved in the corresponding brand finished products (Wegovy / Ozempic and Zepbound / Mounjaro respectively). Compounded preparations are not themselves FDA-approved as drugs.
    • Eligibility for GLP-1 treatment is determined by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal/family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Most are mild-to-moderate and concentrated during dose escalation. Severe gastrointestinal symptoms causing dehydration can increase acute kidney injury risk and should be reported to the prescribing clinician.
    • Trimi's clinical review is coordinated by Dr. Asad Niazi, MD MPH through Beluga Health's 50-state physician network. Trimi pricing: $99/month for compounded semaglutide and $125/month for compounded tirzepatide on the annual plan; flat across all prescribed doses within whichever plan, with no enrollment / consultation / shipping fees.
    • This is general information based on the cited sources, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: March 2, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    2. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    3. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Evidence-based comparison of GLP-1 medications vs Weight Watchers for weight loss. Compare real results, costs, long-term success rates, and which program delivers lasting results.

    Compare the annual costs of GLP-1 maintenance vs active weight loss dosing. Covers brand vs compounded pricing, insurance strategies, and how dose reduction saves money.

    Step-by-step retatrutide injection: 6-day half-life, once-weekly dosing, site rotation, and how to time shots for fewer side effects and better weight loss results.

    Guide to semaglutide 0.5mg dose increase. Learn what to expect at the first titration step, typical side effects, weight loss results, and when to advance to 1.0mg.

    Start your GLP-1 journey — from $99/mo

    Get Started